327 related articles for article (PubMed ID: 33764774)
1. Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery.
Pei J; Wang G; Feng L; Zhang J; Jiang T; Sun Q; Ouyang L
J Med Chem; 2021 Apr; 64(7):3493-3507. PubMed ID: 33764774
[TBL] [Abstract][Full Text] [Related]
2. LYST affects lysosome size and quantity, but not trafficking or degradation through autophagy or endocytosis.
Holland P; Torgersen ML; Sandvig K; Simonsen A
Traffic; 2014 Dec; 15(12):1390-405. PubMed ID: 25216107
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
4. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
[TBL] [Abstract][Full Text] [Related]
5. Targeted protein degradation in drug development: Recent advances and future challenges.
Song J; Hu M; Zhou J; Xie S; Li T; Li Y
Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
[TBL] [Abstract][Full Text] [Related]
6. A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy.
Wang J; Wang Y; Yang F; Luo Q; Hou Z; Xing Y; Lu F; Li Z; Yin F
ACS Chem Biol; 2024 May; 19(5):1161-1168. PubMed ID: 38662199
[TBL] [Abstract][Full Text] [Related]
7. Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond.
Zhong Y; Chi F; Wu H; Liu Y; Xie Z; Huang W; Shi W; Qian H
Eur J Med Chem; 2022 Mar; 231():114142. PubMed ID: 35092900
[TBL] [Abstract][Full Text] [Related]
8. Lysosome-targeting chimaeras for degradation of extracellular proteins.
Banik SM; Pedram K; Wisnovsky S; Ahn G; Riley NM; Bertozzi CR
Nature; 2020 Aug; 584(7820):291-297. PubMed ID: 32728216
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
Vogelmann A; Robaa D; Sippl W; Jung M
Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
[TBL] [Abstract][Full Text] [Related]
10. Measuring the Overall Rate of Protein Breakdown in Cells and the Contributions of the Ubiquitin-Proteasome and Autophagy-Lysosomal Pathways.
Sha Z; Zhao J; Goldberg AL
Methods Mol Biol; 2018; 1844():261-276. PubMed ID: 30242715
[TBL] [Abstract][Full Text] [Related]
11. Cadmium-induced cytotoxicity in mouse liver cells is associated with the disruption of autophagic flux via inhibiting the fusion of autophagosomes and lysosomes.
Zou H; Wang T; Yuan J; Sun J; Yuan Y; Gu J; Liu X; Bian J; Liu Z
Toxicol Lett; 2020 Mar; 321():32-43. PubMed ID: 31862506
[TBL] [Abstract][Full Text] [Related]
12. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
Liang Y; Nandakumar KS; Cheng K
Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
[TBL] [Abstract][Full Text] [Related]
13. Targeted Protein Degradation via Lysosomes.
Paudel RR; Lu D; Roy Chowdhury S; Monroy EY; Wang J
Biochemistry; 2023 Feb; 62(3):564-579. PubMed ID: 36130224
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras.
Ahn G; Riley NM; Kamber RA; Wisnovsky S; Moncayo von Hase S; Bassik MC; Banik SM; Bertozzi CR
Science; 2023 Oct; 382(6668):eadf6249. PubMed ID: 37856615
[TBL] [Abstract][Full Text] [Related]
15. Lysosome and related protein degradation technologies.
Zheng H; Li G; Min J; Xu X; Huang W
Drug Discov Today; 2023 Nov; 28(11):103767. PubMed ID: 37708931
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
Tomaselli D; Mautone N; Mai A; Rotili D
Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
[TBL] [Abstract][Full Text] [Related]
17. Multifaceted targeted protein degradation systems for different cellular compartments.
Zorca CE; Fallahi A; Luo S; Eldeeb MA
Bioessays; 2022 Jun; 44(6):e2200008. PubMed ID: 35417040
[TBL] [Abstract][Full Text] [Related]
18. PROTACs- a game-changing technology.
Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
[No Abstract] [Full Text] [Related]
19. PROTACs: New method to degrade transcription regulating proteins.
Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
[TBL] [Abstract][Full Text] [Related]
20. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
Alabi SB; Crews CM
J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
